109906
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
子宫内膜癌发生发展相关关键基因的鉴定
Authors Huang M, Zhu Q, Tan K, Chen X
Received 1 August 2025
Accepted for publication 2 October 2025
Published 8 November 2025 Volume 2025:17 Pages 4311—4321
DOI https://doi.org/10.2147/IJWH.S554568
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Matteo Frigerio
Meiyuan Huang,1 Qiong Zhu,2 Kai Tan,3 Xupeng Chen4
1Department of Pathology, Zhuzhou Central Hospital, Zhuzhou, Hunan, 412000, People’s Republic of China; 2Department of Obstetrics and Gynecology, Zhuzhou Central Hospital, Zhuzhou, Hunan, 412000, People’s Republic of China; 3Department of Radiology, Zhuzhou Central Hospital, Zhuzhou, Hunan, 412000, People’s Republic of China; 4Department of Laboratory, Zhuzhou Central Hospital, Zhuzhou, Hunan, 412000, People’s Republic of China
Correspondence: Xupeng Chen, Department of Laboratory, Zhuzhou Central Hospital, Zhuzhou, Hunan, 412000, People’s Republic of China, Email 460651921@qq.com
Object: Endometrial cancer (EC) is one of the most common gynecologic malignancies, for which endometrial hyperplasia (EH) and type 2 diabetes are established high-risk factors. However, the common molecular mechanisms underlying this association remain poorly understood. This study therefore aimed to identify and validate hub genes linking EH, type 2 diabetes, and EC, and to assess their prognostic value.
Methods: Intersection genes among EH and EC DEGs (GSE106191) and type 2 diabetes-related genes (GeneCards) were screened. A prognostic model was constructed via Lasso-Cox regression in TCGA-UCEC. Functional enrichment (GO and KEGG) analyzed the prognostic model. The PPI network identified hub genes within the prognostic model. Subsequent prognostic analysis in TCGA-UCEC validated key hub genes. Their expression was further analyzed across GSE106191 and TCGA-UCEC datasets and confirmed via immunohistochemistry. Correlations with clinical features (age, stage, grade, TP53 mutation, weight) in EC were assessed using UALCAN.
Results: One hundred and sixty-two intersection genes were identified. The 16-gene prognostic model stratified EC patients into high/low-risk groups with significantly distinct overall survival (HR = 3.475, P = 2.51e-7; 1/3/5-year AUCs: 0.740/0.749/0.783). Functional enrichment linked genes to TGF-beta signaling and estrogen pathways. Combined PPI network analysis and prognostic validation identified PGR and VIM as key hub genes, both significantly downregulated in EC versus normal tissues across TCGA-UCEC and GSE106191 datasets (P < 0.05; IHC confirmed). Notably, within tumor samples, PGR and VIM expression was significantly higher in EC patients with diabetes compared to those without diabetes. Immunohistochemistry confirmed the downregulation of PGR and VIM protein expression in EC tissues compared to normal and EH tissues. Their expression correlated with clinical characteristics (age, stage, histology, TP53 mutation, weight) and was elevated in diabetic EC patients (P < 0.05).
Conclusion: PGR and VIM were identified as DEGs of EH, type 2 diabetes, and EC. Their reduced expression in EC correlated with poorer prognosis, underscoring their potential as prognostic biomarkers and therapeutic targets, especially in diabetic EC patients. In this study, we offer a new genetic biomarker for the prediction of EC patients’ prognosis.
Keywords: endometrial hyperplasia, endometrial cancer, type 2 diabetes, prognostic
1Department of Pathology, Zhuzhou Central Hospital, Zhuzhou, Hunan, 412000, People’s Republic of China; 2Department of Obstetrics and Gynecology, Zhuzhou Central Hospital, Zhuzhou, Hunan, 412000, People’s Republic of China; 3Department of Radiology, Zhuzhou Central Hospital, Zhuzhou, Hunan, 412000, People’s Republic of China; 4Department of Laboratory, Zhuzhou Central Hospital, Zhuzhou, Hunan, 412000, People’s Republic of China
Correspondence: Xupeng Chen, Department of Laboratory, Zhuzhou Central Hospital, Zhuzhou, Hunan, 412000, People’s Republic of China, Email 460651921@qq.com
Object: Endometrial cancer (EC) is one of the most common gynecologic malignancies, for which endometrial hyperplasia (EH) and type 2 diabetes are established high-risk factors. However, the common molecular mechanisms underlying this association remain poorly understood. This study therefore aimed to identify and validate hub genes linking EH, type 2 diabetes, and EC, and to assess their prognostic value.
Methods: Intersection genes among EH and EC DEGs (GSE106191) and type 2 diabetes-related genes (GeneCards) were screened. A prognostic model was constructed via Lasso-Cox regression in TCGA-UCEC. Functional enrichment (GO and KEGG) analyzed the prognostic model. The PPI network identified hub genes within the prognostic model. Subsequent prognostic analysis in TCGA-UCEC validated key hub genes. Their expression was further analyzed across GSE106191 and TCGA-UCEC datasets and confirmed via immunohistochemistry. Correlations with clinical features (age, stage, grade, TP53 mutation, weight) in EC were assessed using UALCAN.
Results: One hundred and sixty-two intersection genes were identified. The 16-gene prognostic model stratified EC patients into high/low-risk groups with significantly distinct overall survival (HR = 3.475, P = 2.51e-7; 1/3/5-year AUCs: 0.740/0.749/0.783). Functional enrichment linked genes to TGF-beta signaling and estrogen pathways. Combined PPI network analysis and prognostic validation identified PGR and VIM as key hub genes, both significantly downregulated in EC versus normal tissues across TCGA-UCEC and GSE106191 datasets (P < 0.05; IHC confirmed). Notably, within tumor samples, PGR and VIM expression was significantly higher in EC patients with diabetes compared to those without diabetes. Immunohistochemistry confirmed the downregulation of PGR and VIM protein expression in EC tissues compared to normal and EH tissues. Their expression correlated with clinical characteristics (age, stage, histology, TP53 mutation, weight) and was elevated in diabetic EC patients (P < 0.05).
Conclusion: PGR and VIM were identified as DEGs of EH, type 2 diabetes, and EC. Their reduced expression in EC correlated with poorer prognosis, underscoring their potential as prognostic biomarkers and therapeutic targets, especially in diabetic EC patients. In this study, we offer a new genetic biomarker for the prediction of EC patients’ prognosis.
Keywords: endometrial hyperplasia, endometrial cancer, type 2 diabetes, prognostic